WeVote
Log In

Bill

Bill

SB 206

Hyperbaric oxygen treatment program.

2025 Regular Session Introduced by Blake Doriot and 1 co-sponsor

Indiana bill SB 206 creates a hyperbaric oxygen treatment program, likely targeting veterans, pending committee review and full bill text release.

Senator Doriot added as coauthor
#agencies;departmentofhealth(idoh) #agencies;departmentofveteran'saffairs(dva) #armedforces;benefits #armedforces;servicemembers #armedforces;spousesanddependents #stategovernment;stateandlocalfunding #veterans
0
WeVote Research Nonpartisan
Bill Summary · SB 206

Legislative bill overview

SB 206 establishes a hyperbaric oxygen treatment program in Indiana, though the bill text is not publicly available yet to specify exact details. Based on the committee referral to Veterans Affairs, the program likely targets veterans or military-connected populations. The bill is in early legislative stages with recent author additions suggesting ongoing development.

Why is this important

Hyperbaric oxygen therapy (HBOT) is used to treat conditions like diabetic wounds, carbon monoxide poisoning, and certain non-healing injuries. If this program expands access or funding for HBOT in Indiana—particularly for underserved populations like veterans—it could improve treatment outcomes for specific medical conditions. The cost implications and eligibility criteria will significantly affect the program's real-world impact.

Potential points of contention

  • Program cost and state budget impact: HBOT is expensive; unclear whether the program requires new appropriations or relies on existing budgets
  • Eligibility criteria: Whether the program serves only veterans, all Hoosiers, or specific medical conditions will determine affected populations
  • Medical evidence requirements: Questions about which conditions qualify for coverage and whether standards align with current medical consensus on HBOT effectiveness

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.